NYSE:NVS

Novartis (NVS) Stock Forecast, Price & News

$98.91

+1.80 (+1.85%)

(As of 06/2/2023 ET)

Compare

Today's Range: $97.89
▼
$98.93
50-Day Range: $90.19
▼
$104.91
52-Week Range: $74.09
▼
$105.56

Volume: 3.74 million shs
Average Volume: 1.85 million shs
Market Capitalization: $209.65 billion

P/E Ratio: 30.43
Dividend Yield: 2.30%
Price Target: $82.25

Novartis MarketRank™ Forecast

Analyst Rating: Hold
2.09 Rating Score
Upside/Downside: 16.8% Downside
$82.25 Price Target
Short Interest: Healthy
0.22% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.16
Based on 17 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 8.25%
From $6.67 to $7.22 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

589th out of 980 stocks

Pharmaceutical Preparations Industry

296th out of 485 stocks

1.1

Analyst's Opinion

Consensus Rating
Novartis has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 3 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $82.25, Novartis has a forecasted downside of 16.8% from its current price of $98.91.
Amount of Analyst Coverage
Novartis has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.22% of the float of Novartis has been sold short.
Short Interest Ratio / Days to Cover
Novartis has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Novartis has recently decreased by 10.46%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Yield
Novartis pays a meaningful dividend of 2.30%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Novartis has only been increasing its dividend for 4 years.
Dividend Coverage
The dividend payout ratio of Novartis is 69.85%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Novartis will have a dividend payout ratio of 31.44% next year. This indicates that Novartis will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NVS.

1.8

News and Social Media Coverage

News Sentiment
Novartis has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for Novartis this week, compared to 6 articles on an average week.
Search Interest
Only 19 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novartis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.01% of the stock of Novartis is held by insiders.
Percentage Held by Institutions
Only 8.12% of the stock of Novartis is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Novartis are expected to grow by 8.25% in the coming year, from $6.67 to $7.22 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novartis is 30.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.83.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novartis is 30.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.48.
Price to Earnings Growth Ratio
Novartis has a PEG Ratio of 1.65. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Novartis has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Novartis (NYSE:NVS) Stock

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

June 1, 2023 | marketbeat.com

20 Best Healthcare Dividend Stocks to Invest in (NVS)

Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.

May 31, 2023 | marketbeat.com

The How and Why of Investing in Biotech Stocks (NVS)

One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccines

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

May 30, 2023 | marketbeat.com

Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application (NVS)

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin

May 18, 2023 | marketbeat.com

Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market (NVS)

Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.

June 4, 2023 | americanbankingnews.com

Novartis AG (NYSE:NVS) Receives $84.40 Consensus Price Target from Analysts

June 2, 2023 | bloomberg.com

Novartis’s Kisqali Cut Risk of Cancer’s Return 25% in Trial

June 2, 2023 | msn.com

Novartis CEO Vas Narasimhan on the latest research on a breast cancer drug

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

June 2, 2023 | markets.businessinsider.com

Novartis Says Kisqali And Endocrine Therapy Reduces Cancer Recurrence Risk By 25%

June 2, 2023 | msn.com

Novartis says breast cancer pill Kisqali cut risk of recurrence by 25%

June 2, 2023 | msn.com

Here's Why Novartis (NVS) Is a Great 'Buy the Bottom' Stock Now

June 1, 2023 | msn.com

Looking At Novartis's Recent Unusual Options Activity

June 1, 2023 | finance.yahoo.com

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis

May 31, 2023 | finance.yahoo.com

5 Large Drug Stocks to Watch From a Thriving Industry

May 29, 2023 | finance.yahoo.com

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

May 26, 2023 | msn.com

EMA recommends revoking approval of Novartis' sickle cell disease drug Adakveo in EU

May 25, 2023 | markets.businessinsider.com

Sandoz : EMA Accepts MAA For Proposed Biosimilar Denosumab

May 23, 2023 | bizjournals.com

Former Novartis executive director heads up new immuno-oncology startup

May 22, 2023 | msn.com

Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis

May 22, 2023 | msn.com

Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis

May 22, 2023 | msn.com

Avrobio Soars on Offloading Gene Therapy to Novartis for $87.5M

May 19, 2023 | msn.com

Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio

May 19, 2023 | barrons.com

Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations

May 15, 2023 | msn.com

Novartis appoints 10-member board for Sandoz unit ahead of spinoff

May 12, 2023 | americanbankingnews.com

Brokerages Set Novartis AG (NYSE:NVS) PT at $84.40

May 11, 2023 | americanbankingnews.com

Novartis AG (NYSE:NVS) Forecasted to Earn Q2 2023 Earnings of $1.64 Per Share

See More Headlines

NVS Price History

30 days | 90 days | 365 days | Advanced Chart

NVS Company Calendar

Ex-Dividend for 3/20 Dividend: 3/09/2023
Dividend Payable: 3/20/2023
Last Earnings: 4/25/2023
Today: 6/04/2023
Next Earnings (Estimated): 7/18/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:NVS
CUSIP: N/A
CIK: 1114448
Web: www.novartis.com
Phone: (161) 324-1111
Fax: 41-61-324-7826
Employees: 101,703
Year Founded: 1996

Price Target and Rating

Average Stock Price Forecast: $82.25
High Stock Price Forecast: $90.00
Low Stock Price Forecast: $70.00
Forecasted Upside/Downside: -16.8%
Consensus Rating: Hold
Rating Score (0-4): 2.10
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.25
Trailing P/E Ratio: 30.43
Forward P/E Ratio: 14.83
P/E Growth: 1.65
Net Income: $6.96 billion
Net Margins: 13.78%
Pretax Margin: 16.56%
Return on Equity: 23.29%
Return on Assets: 11.64%

Debt

Debt-to-Equity Ratio: 0.39
Current Ratio: 1.05
Quick Ratio: 0.79

Sales & Book Value

Annual Sales: $50.55 billion
Price / Sales: 4.15
Cash Flow: $6.30 per share
Price / Cash Flow: 15.70
Book Value: $24.60 per share
Price / Book: 4.02

Miscellaneous

Outstanding Shares: 2,119,600,000
Free Float: 2,119,388,000
Market Cap: $209.65 billion
Optionable: Optionable
Beta: 0.54

Social Links

Key Executives

Vasant Narasimhan
Chief Executive Officer

Steffen Lang
President-Operations

Harry Werner Kirsch
Chief Financial Officer

Shreeram Aradhye
Chief Medical Officer

Klaus Moosmayer
Chief Ethics, Risk & Compliance Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NVS Stock - Frequently Asked Questions

Should I buy or sell Novartis stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings or view top-rated stocks.
What is Novartis' stock price forecast for 2023?: 10 Wall Street analysts have issued twelve-month price objectives for Novartis' shares. Their NVS share price forecasts range from $70.00 to $90.00. On average, they expect the company's stock price to reach $82.25 in the next year. This suggests that the stock has a possible downside of 16.8%.
View analysts price targets for NVS or view top-rated stocks among Wall Street analysts.
How have NVS shares performed in 2023?: Novartis' stock was trading at $90.72 at the beginning of 2023. Since then, NVS stock has increased by 9.0% and is now trading at $98.91.
View the best growth stocks for 2023 here.
When is Novartis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 18th 2023.
View our NVS earnings forecast.
How were Novartis' earnings last quarter?: Novartis AG (NYSE:NVS) issued its quarterly earnings data on Tuesday, April, 25th. The company reported $1.71 EPS for the quarter, beating the consensus estimate of $1.55 by $0.16. The business earned $12.95 billion during the quarter, compared to analysts' expectations of $12.60 billion. Novartis had a net margin of 13.78% and a trailing twelve-month return on equity of 23.29%. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.46 EPS.
How often does Novartis pay dividends? What is the dividend yield for Novartis?: Novartis declared an annual dividend on Thursday, February 2nd. Stockholders of record on Friday, March 10th will be given a dividend of $3.4694 per share on Monday, March 20th. This represents a yield of 2.6%. The ex-dividend date is Thursday, March 9th. This is a positive change from the stock's previous annual dividend of $1.18.
Read our dividend analysis for NVS.
Is Novartis a good dividend stock?: Novartis (NYSE:NVS) pays an annual dividend of $2.27 per share and currently has a dividend yield of 2.30%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 69.85%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 31.44% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.
What is Vas Narasimhan's approval rating as Novartis' CEO?: 938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).
What is Novartis' stock symbol?: Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
Who are Novartis' major shareholders?: Novartis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dodge & Cox (0.96%), Envestnet Asset Management Inc. (0.40%), Bank of America Corp DE (0.36%), Franklin Resources Inc. (0.33%), Dimensional Fund Advisors LP (0.29%) and Charles Schwab Investment Management Inc. (0.21%).
How do I buy shares of Novartis?: Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Novartis' stock price today?: One share of NVS stock can currently be purchased for approximately $98.91.
How much money does Novartis make?: Novartis (NYSE:NVS) has a market capitalization of $209.65 billion and generates $50.55 billion in revenue each year. The company earns $6.96 billion in net income (profit) each year or $3.25 on an earnings per share basis.
How many employees does Novartis have?: The company employs 101,703 workers across the globe.
Does Novartis have any subsidiaries?: The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
How can I contact Novartis?: Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The official website for the company is www.novartis.com. The company can be reached via phone at (161) 324-1111, via email at investor.relations@novartis.com, or via fax at 41-61-324-7826.

This page (NYSE:NVS) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Novartis (NVS) Stock Forecast, Price & News

Novartis MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Novartis (NYSE:NVS) Stock

NVS Stock News Headlines

NVS Price History

NVS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

NVS Stock - Frequently Asked Questions

Overall MarketRank^™